The Role of and Selection Process for the New Anticoagulants in Nonvalvular Atrial Fibrillation

Dr. James Reiffel from Columbia University Medical Center, New York, NY moderated the topic "The Role of and Selection Process for the New Anticoagulants in Nonvalvular Atrial Fibrillation" with Drs. Jonathan Halperin from Mount Sinai Medical Center, New York, NY, Peter Kowey from the Lankenau Institute for Medical Research, Jefferson Medical College, Wynnewood, PA, and Gerald Naccarelli from Penn State University College of Medicine, Hershey, PA. The discussion focused primarily on: (1) The definition of nonvalvular atrial fibrillation (2) the advantages and disadvantages of warfarin (3) the pharmacology of the new anticoagulants (4) the major clinical trials that led to the approval of the new anticoagulants (5) determining what anticoagulant to use in patients already on warfarin—“starters” versus “switchers.” (Med Roundtable Cardiovasc Ed. 2012;3(3):143–151) ©2012 FoxP2 
Media, LLC